Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Metastatic melanoma: MART-1 T-cell receptor modified T-cells

Maartje Rohaan • 28 Sep 2019
ESMO 2019
Melanoma Skin Cancer

Maartje Rohaan, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, describes the results from the Phase I trial of MART-1 T-cell receptor-modified T-cells in patients with metastatic melanoma and goes on to describe where she sees the field moving in the future. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Maartje Rohaan

0:51
What role will TILs play in treating patients with melanoma?
Maartje Rohaan • 29 Nov 2022
3:00
The impact of metastasectomy in patients with melanoma receiving TILs
Maartje Rohaan • 29 Nov 2022
1:04
Optimizing TILs as a novel immunotherapy strategy in metastatic melanoma
Maartje Rohaan • 29 Nov 2022
0:47
Adoptive cell therapy in metastatic melanoma
Maartje Rohaan • 28 Sep 2019

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals